17 . October , 2018 - Wednesday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Ondansetron Hydrochloride

Big Image Pronouncation: (ahn-DAN-SEH-trahn HIGH-droe-KLOR-ide)
Class: 5-HT 3 receptor antagonist

Trade Names:
- Tablets 4 mg (as HCl dihydrate)
- Tablets 8 mg (as HCl dihydrate)
- Tablets 24 mg (as HCl dihydrate)
- Solution, oral 4 mg/5 mL (5 mg as HCl dihydrate)
- Injection 2 mg/mL (as HCl dihydrate)
- Injection 32 mg/50 mL (as HCl dihydrate)

Trade Names:
Zofran ODT
- Tablets, orally-disintegrating 4 mg (as base)
- Tablets, orally-disintegrating 8 mg (as base)

Mechanism of Action


Selective serotonin (5-HT 3 ) receptor antagonist that inhibits serotonin receptors in GI tract or chemoreceptor trigger zone.



Passively and completely absorbed from GI tract. Bioavailability is 48% to 75% and is slightly enhanced with food.

C max for males is 24.1 to 37 ng/mL (8 mg oral dose). C max for females is 42.7 to 52.4 ng/mL (8 mg oral dose). C max for injection is 102 to 170 ng/mL. T max for males is 2 to 4.1 hr (8 mg dose). T max for females is 1.7 to 4.9 hr (8 mg dose).


Plasma protein binding is 70% to 76%.


Extensively metabolized in the liver by hydroxylation, followed by glucuronide or sulfate conjugation; CYP1A2, CYP2D6, CYP3A4 are the main hepatic enzymes.


Approximately 5% is eliminated as parent compound in urine. The t ½ for males is 2.1 to 4.5 hr (8 mg oral dose). The t ½ for females is 1.9 to 6.2 hr (8 mg dose). The t ½ for injection is 3.5 to 5.5 hr. Plasma clearance is 0.262 to 0.381 L/hr/kg.

Special Populations


In elderly over 75 yr, there is a reduction in clearance and an increase in elimination half-life. No dosage adjustment is necessary.


The extent and rate of absorption is greater in women than in men. There is slower clearance, a smaller volume of distribution, and higher bioavailability in women.

Severe Hepatic Insufficiency

Clearance is reduced 2- to 3-fold. The volume of distribution is increased. The half-life is increased to 20 hr. Bioavailability approaches 100%. A total daily dose of 8 mg should not be exceeded.

Severe Renal Insufficiency

There is a reduction in clearance. Oral plasma clearance was reduced by 50%. No dosage adjustment is necessary.

Indications and Usage

Parenteral and oral

Prevention of nausea and vomiting with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin; prevention of postoperative nausea or vomiting.


Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin 50 mg/m 2 or more.

Unlabeled Uses

Treatment of nausea and vomiting associated with acetaminophen poisoning or prostacyclin therapy; treatment of acute levodopa-induced psychosis (visual hallucinations); reduction in bulimic episodes due to bulimia nervosa; treatment of spinal or epidural morphine-induced pruritus; management of social anxiety disorder.


Standard considerations.

Dosage and Administration

Prevention of Chemotherapy-Induced Nausea and Vomiting

IV 0.15 mg/kg infused over 15 min beginning 30 min before emetogenic chemotherapy with 2 additional 0.15 mg/kg doses 4 and 8 hr after the first dose. Alternatively, infuse 32 mg over 15 min, starting 30 min prior to emetogenic chemotherapy.

Adults and children 12 yr and older

PO (moderately emetogenic cancer chemotherapy) 8 mg bid, administering the first dose 30 min prior to starting emetogenic chemotherapy and the second dose 8 hr after the first dose; subsequent 8 mg doses may be given q 12 hr for 1 to 2 days after completion of chemotherapy.

Children 4 to 11 yr

PO 4 mg tid, starting 30 min prior to chemotherapy, with subsequent doses 4 and 8 hr after the first dose; give 4 mg q 8 hr for 1 to 2 days after completion of chemotherapy.

Prevention of Radiotherapy-Induced Nausea and Vomiting

PO 8 mg tid.

Total Body Irradiation

PO 8 mg 1 to 2 hr prior to each fraction of radiotherapy administered each day.

Single High-Dose Fraction Radiotherapy to the Abdomen

PO 8 mg 1 to 2 hr prior to radiotherapy, with subsequent doses q 8 hr after the first dose for 1 to 2 days after completion of radiotherapy.

Daily Fractionated Radiotherapy to the Abdomen

PO 8 mg 1 to 2 hr prior to radiotherapy, with subsequent doses q 8 hr after the first dose for each day radiotherapy is given.

Prevention of Postoperative Nausea and Vomiting

IV 4 mg (undiluted) over 30 sec (preferably over 2 to 5 min) or IM 4 mg (undiluted) as a single injection. PO 16 mg as a single dose 1 hr prior to induction of anesthesia.

Children (2 to 12 yr weighing 40 kg or less)

IV 0.1 mg/kg

Children (more than 40 kg)

IV 4 mg single dose. Administer over 30 sec or longer, preferably over 2 to 5 min.

Prevention of Nausea and Vomiting due to Highly Emetogenic Cancer Chemotherapy

PO 24 mg given 30 min prior to start of single-day highly emetogenic chemotherapy, including 50 mg/m 2 or more cisplatin.

Drug Interactions

Rifamycins (eg, rifampin)

Plasma levels of ondansetron may be reduced, decreasing the antiemetic effect.


Alkaline solutions.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Chest pain; tachycardia.


Headache; seizures.




Dry mouth; constipation; abdominal pain.






Fever; anaphylaxis; weakness.



Category B .




Dosing in children younger than 4 yr is not well defined.

Hepatic Function

In patients with severe hepatic impairment, do not exceed 8 mg/day oral dose. For IV use, give single 8 mg/day dose over 15 min beginning 30 min before chemotherapy.


Ondansetron does not stimulate gastric or intestinal peristalsis; may mask progressive ileus or gastric distention.



Hypotension, constipation.

Patient Information

  • Advise patient that headache is a common side effect.
  • Advise patient that medication will greatly reduce likelihood of nausea and vomiting, but that these are still possible.

Recent Drug Updates at DrugIndexOnline:

Apo-Sulfinpyrazone Apo-Sulfinpyrazone
Some commonly used brand names are: In the U.S.— Anturane In Canada— Anturan Apo-Sulfinpyrazone Novopyrazone Generic name product may be available in the U.S. Category Antigout agent Antihyperuricemic Description Sulfinpyrazone (sul-fin-PEER-a-zone) is used in the treatme more...

Augmentin Chewable Tablets Augmentin Chewable Tablets
Generic Name: Amoxicillin/Clavulanate Chewable Tablets 125 and 250 mg (a-MOX-i-SIL-in/KLAV-ue-la-nate) Brand Name: AugmentinAugmentin Chewable Tablets is used for:Treating infections caused by certain bacteria. Augmentin Chewable Tablets is a penicillin antibiotic. It works by killing sensitive more...

Chlorthalidone Chlorthalidone
Some commonly used brand names are: In the U.S.— Aquatensen 6 Diucardin 5 Diulo 7 Diuril 2 Enduron 6 Esidrix 4 Hydro-chlor 4 Hydro-D 4 HydroDIURIL 4 Hydromox 9 Hygroton 3 Metahydrin 10 Microzide 4 Mykrox 7 Naqua 10 Naturetin 1 Oretic 4 Renese 8 Saluron 5 Thalitone 3 Trichlorex 10 Zaroxoly more...

Imitrex injection Imitrex injection
Generic Name: sumatriptan succinate Dosage Form: Injection Imitrex Description Imitrex (sumatriptan succinate) Injection is a selective 5-hydroxytryptamine1 receptor subtype agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide more...

Increlex Increlex
Generic Name: Mecasermin (mec-A-sir-men) Brand Name: IncrelexIncrelex is used for:Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Increlex is a horm more...

Mexiletine Mexiletine
Some commonly used brand names are: In the U.S.— Mexitil In Canada— Mexitil Category Antiarrhythmic Description Mexiletine (MEX-i-le-teen) belongs to the group of medicines known as antiarrhythmics. It is used to correct irregular heartbeats to a normal rhythm. Mexiletine more...

Pamidronate Pamidronate
Some commonly used brand names are: In the U.S.— Aredia In Canada— Aredia Another commonly used name is APD . Category Antihypercalcemic Bone resorption inhibitor Description Pamidronate (pa-mi-DROE-nate) is used to treat hypercalcemia (too much calcium in the blood) that more...

Prinzide Prinzide
Generic name: Lisinopril, Hydrochlorothiazide Brand names: Prinzide, Zestoretic Why is Prinzide prescribed? Zestoretic is used in the treatment of high blood pressure. It combines an ACE inhibitor drug with a diuretic. Lisinopril, the ACE inhibitor, works by limiting production of a substance t more...